title: [Retinopathy of prematurity - pathophysiologic mechanisms and new treatment options].
abstract: Retinopathy of prematurity (ROP), like other angioproliferative retinal disorders, has witnessed the advent of anti-VEGF therapy in clinical practice. The first report from the BEAT-ROP study published in 2011 represents the first comparison of anti-VEGF therapy versus conventional laser treatment in a randomised controlled trial. This review article investigates these novel aspects of ROP therapy from a pathophysiological angle and delineates the stages of ROP in which anti-VEGF treatment appears as a reasonable option. Furthermore, the novel chances of anti-VEGF therapy are being weighed against some still unanswered questions and novel study concepts are being presented.
authors.affiliation: Universitäts-Augenklinik, Albert-Ludwigs-Universität, Freiburg. andreas.stahl@uniklinik-freiburg.de
authors.forename: A
authors.initials: A
authors.lastname: Stahl
authors.forename: S
authors.initials: S
authors.lastname: Aisenbrey
authors.forename: T U
authors.initials: TU
authors.lastname: Krohne
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D053685:Laser Therapy / Q000639:trends*; D008297:Male; D013508:Ophthalmologic Surgical Procedures / Q000639:trends*; D012178:Retinopathy of Prematurity / Q000503:physiopathology / Q000601:surgery*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A